APONTIS PHARMA and Zentiva Group have signed an investor agreement on the basis of which Zentiva Group will launch a voluntary public purchase offer for the shares of APONTIS PHARMA. In this context, funds advised by Paragon Partners have entered into a purchase agreement for the sale of an approx. 37.5% stake in APONTIS PHARMA to Zentiva Group.
Hengeler Mueller is advising Paragon Partners on the transaction.
Hengeler Mueller team for Paragon
M&A/Corporate: Martin Ulbrich, Oda Christiane Goetzke (both lead, partner, Düsseldorf), Jasmin Atta-Schumacher, Tim Jaeger (both associates, both Düsseldorf),
Regulatory: Jan Schülting (senior associate, Düsseldorf),
Antitrust: Philipp Otto Neideck (partner, Düsseldorf).
